Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Carfilzomib in multiple myeloma
ASPIRE: Carfilzomib-Len-Dex 'A New Standard of Care' for Relapsed Multiple Myeloma | PracticeUpdate
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data | SpringerLink
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib in multiple myeloma
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes | Leukemia
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Carfilzomib in multiple myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram
